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Implant of mesenchymal cells decreases acute cellular 
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Abstract
Objective: The objective of the study was to show adipose tissue-derived mesenchymal stem cells (AD-MSCs) immuno-
modulatory effects in small bowel transplantation (SBTx). Materials and methods: Forty Wistar Han rats (age: 10-12 weeks): 
were allogenic receptor rats and were allotted in 2 groups. Control group: rats undergoing orthopic SBTx ; AD-MSCs group: 
rats undergoing orthotopic SBTx plus AD-MSCs. Male Lewis rats were allogeneic small bowel donors. Rejection was confirmed 
by histological study of the explanted intestine, enterocyte apoptosis was determined in crypts and the lamina propria of the 
small bowel. Cytokine concentration levels (enzyme-linked immunosorbent assay) (interleukin [IL]-4, IL-10, IL-12, IL-17, IL-21, 
IL-23, tumor necrosis factor-alpha, and transforming growth factor [TGF]-b1) and cell percentages (flow cytometry) (CD3+ 
CD4+, CD8+, CD4+/25+, CD8+/25+, CD4+/25+/Foxp3+, and CD8+/25+/Foxp3+) were assessed in peripheral blood preopera-
tively and after death. Results: Treatment with AD-MSCs produced a significantly lower risk of rejection in the first 7 post-
operative days (five rejection cases among 20 rats in the control group and only one case in the AD-MSCs group). Treg cells 
and TGFb1 levels showed a significant increase in the AD-MSCs group. Conclusions: The local implantation of AD-MSC in 
the anastomosis and the intestinal lumen can induce a regulatory immune response, by increasing the percentages of Treg 
cells and TGb-1 levels, leading to a lower risk of acute rejection by cell mediation, in the first 7 days of the intestinal transplant. 
We think that the implantation of AD-MSCs, in the anastomoses and in the lumen of the donor intestine, could give rise to a 
chimera of donor-recipient cells.
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Resumen
Objetivo: Mostrar el efecto inmunomodulador de las células madre mesenquimales (AD-MSCs) en el trasplante de intestino 
delgado (SBTx). Método: 40 ratas Wistar Han (edad: 10-12 semanas): grupo control (SBTx) y grupo AD-MSCs (SBTx + AD-
MSCs implantadas en las anastomosis distal y proximal del intestino delgado y en la luz intestinal). El intestino delgado pro-
vino de ratas Lewis. El rechazo se confirmó histológicamente. Se estudió la apoptosis de los enterocitos en las criptas y en 
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Introduction
Patients with intestinal failure due to different causes 
who fail total parenteral nutrition require small bowel 
transplantation (SBTx) as the only possible treatment. 
SBTx is increasing in clinical procedures, due to ad-
vances in surgical techniques and immunosuppressant 
treatments. The specific immune response from SBTx 
induces a major risk of rejection and infection as com-
pared to other solid organ transplantation. Acute and 
chronic rejection and post-operative infections after 
SBTx remain the most feared complications. Some au-
thors have reported that control of the acute cellular 
rejection (ACR) improves early graft survival and may 
enhance long-time survival1. In addition, subclinical al-
logeneic rejection in the initial post-operative period of 
SBTx shows a negative influence on graft survival2.
After achieving the differentiation, obtaining, and 
cultivation of mesenchymal stem cells (MSCs), there 
have been early clinical studies on tissue regenera-
tion, to achieve a cure for various diseases through 
the implant3-6. In this decade, there have been some 
studies that refer to the possible role of MSCs in the 
transplantation of organs and tissues7-10 and more re-
cently intestinal transplantation11-14. The first results 
are encouraging, but the biological aspects are still 
unknown at the cellular and molecular level, the re-
generative process obtained, and especially the im-
mune response involved in tissue regeneration, 
inflammatory process, and possible immunomodula-
tion of these cells to prevent or mitigate rejection. 
Experiments “in vitro” and “ex vivo” show a large im-
munomodulator potential of MSCs and the absence of 
adverse effects in clinical application, in particular in 
many aspects of surgery: acute inflammatory reaction 
after surgical trauma, healing of wounds, vascular and 
visceral anastomoses, and the rejection of organ and 
tissue transplants. Intestinal transplantation in human 
clinical practice may be benefited by MSCs use, 
because it currently has a higher percentage of fail-
ures, due to the increased incidence and severity of 
rejection and the occurrence of serious infections. 
Nevertheless, experimental results are far from being 
able to be transferred to human clinical practice.
In experimental studies, the majority of authors in-
fuse MSCs in arterial or venous systems and conclude 
that the immunomodulatory effects of inoculation of 
mesenchymal cells systemically (in the bloodstream) 
are similar to those obtained by local administration 
(in this case, the transplanted organ); these authors 
think that immunomodulatory effects produced by 
mesenchymal cells are independent of the mode of 
administration and delivery of cell implant, in animal 
models. Following Gao et al.14 and Lam et al.15, we 
think that most infused MSCs are trapped by the lung; 
in addition, systemic arterial infusion could induce 
embolism or occlusion. Some authors have studied 
immunological response in SBTx since 199216,17. In the 
present study, we obtained AD-MSCs from adipose 
tissue of a syngeneic animal, therefore in human clini-
cal practice, it could be obtained from the recipient. 
We tried to avoid rejection by means of local implanta-
tion of AD-MSCs in anastomoses and intestinal lumen 
during SBTx surgery. Regarding the immune re-
sponse, this study seeks to obtain a donor-recipient 
cell immunological chimera by means of AD-MSCs 
activating Treg cells function and moderating immune 
response through the Th1 pathway. 
Materials and methods
Animals
Male Wistar Han rats (280-340 g) (age: 10-12 weeks) 
were employed as SBTx orthotopic receptors and to 
obtain AD-MSCs, and male Lewis rats (200-220 g) 
were employed as allogeneic SBTx donors. Animals 
were obtained from the laboratory (IFFA Inc., Lyon, 
France) and were housed individually in standard 
la lámina propia del intestino delgado. Se determinaron por ELISA las citocinas (IL-4, IL-10, IL-12, IL-17, IL-21, IL-23, TNF-α, 
TGF-b1) en sangre periférica y por citometría de flujo los porcentajes celulares (CD3+ CD4+, CD8+, CD4+/25+, CD8+/25+, 
CD4+/25+/Foxp3+, CD8+/25+/Foxp3+) en el preoperatorio y después de la muerte. Resultados: El empleo de AD-MSCs se 
asoció a una disminución significativa del riesgo de rechazo en los primeros 7 días posoperatorios (cinco casos de rechazo 
de 20 ratas en el grupo control y un solo caso en el grupo AD-MSCs). Las células Treg y los valores de TGFb1 mostraron un 
incremento significativo en el grupo AD-MSCs. Conclusiones: El implante local de AD-MSCs en las anastomosis del tras-
plante de intestino delgado podría disminuir el rechazo celular agudo. Pensamos que la implantación de AD-MSCs, en las 
anastomosis y en el lumen del intestino donante, podría dar lugar a un quimera de células donante-receptor.
Palabras clave: Trasplante de intestino. Rechazo. Células madre mesenquimales.
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facilities, maintained on a 12 h light/dark cycle, at 
temperature 22-24°C and provided with commercially 
available chow and water ad libitum. Food was with-
held from both donor and recipient animals for 24 h 
before surgery. All experimental procedures were ap-
proved by the Animal Care and Research Committee 
and were carried out in accordance with EU Directive 
2010/63/EU for animal experiments. Forty Wistar Han 
rats were allotted to two groups: (1) control group, rats 
undergoing orthotopic SBTx (rats receiving placebo: 
normal saline solution) and (2) AD-MSCs group, rats 
undergoing orthotopic SBTx receiving adipose deri-
vate mesenchymal cells.
Surgery procedure
Rats were anesthetized by means of a sevoflurane 
inhalation (4% to induction and 3% to maintain doses). 
After anesthesia, rats received ceftriaxone intramuscu-
larly (50 mg/Kg) and meloxicam (Metacam®, Boehring-
er Ingelheim, Barcelona, Spain) subcutaneously (0.2 
mg/Kg) and underwent surgery using the orthotopic 
SBTx model based on Kort’s orthotopic transplantation 
technique18, with modifications16,17. At the moment of 
carrying out both distal and proximal donor-receptor 
anastomoses, 1 mL of normal serum solution (placebo 
group) or 1 mL normal serum solution containing 1 × 
106 MSCs (AD-MSCs group) were injected in intestinal 
donor subserosal by means of an 8G needle and 2 × 
106 MSCs in intestinal lumen. One day previous to sur-
gery and after surgery, rats received subcutaneously a 
0.2 mg/day dose of cyclosporin (Sandimmun®, Novar-
tis) until the end of the experiment. 
Isolation and characterization of AD-MSCs
Cells were isolated from the abdominal adipose tis-
sue of male Wistar Han rats. MSCs were obtained us-
ing the Zuk et al. technique19. The cells isolated from 
adipose tissue rats were confirmed as AD-MSCs based 
on their morphology, adherence to plastic, and ability 
to differentiate into chondrocytes, adipocytes, osteo-
cytes, and hepatocytes in vitro. Flow cytometry showed 
that the AD-MSC preparations were 95% pure and that 
98% of these cells were positive for CD29, CD90, and 
RT1A and negative for CD34, CD45, and RT1B. 
Clinical manifestations 
Rats underwent euthanasia when showing clinical 
manifestations of rejection, anastomosis dehiscence, 
infection, or severe post-operative complications. 
Deaths occurring within the first 72 post-operative 
hours were attributed to surgical failures and these 
animals were excluded from the study. Allograft rejec-
tion was diagnosed clinically according to the criteria 
of Schraut and Lee20.
Histopathological analysis 
The presence of rejection was confirmed by histo-
logical study of the explanted intestine. Two fragments 
of 1 cm of length containing the proximal and distal 
anastomoses, respectively, plus a portion of intestine 
(1 cm) equidistant from the anastomoses were taken. 
Intestinal tissues were fixed in 10% formalin, embed-
ded in paraffin, and cut into 5 mm sections, which 
were stained with hematoxylin and eosin. The slides 
were blindly reviewed and rejection was graded as (a) 
moderate (great mononuclear cell infiltration of the 
intestinal wall but moderate destruction of villi), (b) 
intense (great mononuclear cell infiltration and de-
struction of villi), and (c) massive (massive mononu-
clear cell infiltration and total destruction of villi). 
Enterocyte apoptosis was determined in crypts and 
the lamina propria of the small bowel by means of the 
Gavrieli et al. technique21.
Flow cytometry
Serum was obtained from peripheral blood of recipi-
ent rats, 10 days before surgery and when euthanasia 
was performed or death was observed. CD3+ CD4+, 
CD8+, CD4+/25+, CD8+/25+ CD4+/25+/Foxp3+, and 
CD8+/25+/Foxp3+ cell percentages were assessed in 
peripheral blood at pre-operative situation and after 
euthanasia procedures or spontaneous death. Cell 
percentages were determined by flow cytometry (Gal-
liosTM Flow Cytometer, Beckman Coulter) using mono-
clonal antibodies (Anti-rat CD25 APC 17-0390 
[eBioscience]; Anti-Mouse/rat Foxp3 PE 12-5773 
[eBioscience]; Anti-Rat CD8a FITC 11-0084 [eBiosci-
ence]; Anti-Rat CD4 FITC 11-0040 [eBioscience]; Anti-
RAT CD45 V450 561587 [BD Horizon]; and RAT T 
lymphocyte Cocktail 558493 [BD Pharmingen]).
Enzymoimmunoanalysis (enzyme-linked 
immunosorbent assay [ELISA])
Recipient serum was obtained from peripheral blood 
10 days before surgery and when euthanasia was per-
formed or death observed. Cytokine concentrations 
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were measured by ELISA kits as described by the 
manufacturers, including comparisons with standard 
curves. Kits used and minimum detectable concentra-
tions of interleukins (IL): IL-4: 1.5 pg/ml (RayBiotech 
Inc., Norcross, GA, USA); IL-10: 10 pg/ml (RayBiotech 
Inc., Norcross, GA, USA); IL-12: 9.375 (Elabscience, 
Bethesda, MD, USA); IL-17: 23.43 pg/ml (Cusabio, Hu-
bei, China); IL-21: 3.3 pg/ml (Merck-Millipore, Billerica, 
MA, USA); IL-23: 0.196 pg/ml (Merck-Millipore, Billeri-
ca, MA, USA); tumor necrosis factor-alpha (TNF-a): 15 
pm/ml (Diaclone, Besancon Cedex, France); and 
transforming growth factor (TGF)-b1: 11.4 pg/ml (Mil-
liplex®, Merck-Millipore, Billerica, MA, USA).
Statistical analysis 
Appearance date, grade of rejection, and spontane-
ous death due to rejection were confirmed by histo-
pathological analysis and apoptosis grade. Data were 
analyzed by means of nonparametric tests: the Mann–
Whitney U-test to study differences between means 
and rates was compared between groups using the 
Kaplan–Meier analysis. Log-rank (Mantel-COX) test-
ing was used to ascertain the significance of survival 
differences between groups22,23. CD3+ CD4+, CD8+, 
CD4+/25+, CD8+/25+ CD4+/25+/Foxp3+, and 
CD8+/25+/foxp3+ cell percentages and cytokine con-
centrations data were analyzed by means of ANOVA 
tests. Differences between groups were compared 
using paired Student’s t-test. p < 0.05 was considered 
statistically significant. Results are expressed as 
mean ± standard deviation. 
Results
Table 1 shows the number of rats undergoing eutha-
nasia or suffering death due to cell acute allograft rejec-
tion or surgical causes and date and also the grade of 
rejection. In AD-MSCs group, one rat died due to rejec-
tion. In the AD-MSCs group, nine rats survived the first 
7 post-operative days, four rats of these underwent eu-
thanasia at the 7th day to obtain necropsy, and none of 
them presented rejection signs. For the late post-oper-
ative period (more than a week after surgery), we stud-
ied five rats in each group: we observed one rejection 
case 12 days after surgery in the control group, and one 
rejection case 16 days after surgery in the AD-MSCs 
group. The remaining rats (three rats in each group) did 
not show signs or symptoms of rejection from the 18th 
post-operative day until euthanasia 4 months after sur-
gery. Figure 1 shows the Kaplan–Meier recipient sur-
vival curve and the statistical study of differences 
between groups with regard to survival and acute rejec-
tion. AD-MSCs improved the recipient survival (death 
due to rejection) (p = 0.002) (Regressión coefficient: 
placebo vs. AD-MSCs p = 0.017; COX regression: 
Table 1. Cause of death and rejection grade in placebo and MSC groups during the first 7 post-operative days















Day of surgery 6 Surgery 6 Surgery
1st 1 Surgery 1 Surgery
4th 1 Rejection Massive Rejection 1 Euthanasia None Anastomoses 
dehiscence
5th 1 Rejection Massive Rejection 1 Euthanasia None Anastomoses 
dehiscence
1 Euthanasia Moderate Rejection 1 Euthanasia None Anastomoses 
dehiscence
1 Euthanasia Lumen hemorrhage
6th 1 Rejection Intense Rejection
1 Euthanasia Anastomoses dehiscence
7th 1 Rejection Massive Rejection 1 Euthanasia Intense Rejection
1 Euthanasia Anastomoses dehiscence
Remaining rats 5 9
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placebo vs. AD-MSCs HR: 13.08). Treatment with AD-
MSCs produced a significantly lower risk of rejection in 
the first 7 post-operative days (five rejection cases in the 
control group and only one case in the AD-MSCs group). 
Treatment with AD-MSCs associated with 92.8% reduc-
tion of the risk of death due to rejection. Figure 2 pres-
ents degrees of rejection assessed morphologically.
We did not find any differences in %CD3, %CD4, 
%CD8, %CD4/25, and %CD8/25 between placebo and 
AD-MSC groups in the pre-operative or in the post-op-
erative studies in peripheral blood. Figures 3 and 4 show 
%CD4/25/FOXp3 and %CD8/25/FOXp3 variations in pe-
ripheral blood, respectively, at pre- and post-operative 
period; at post-operative period, we observed significant-
ly higher cell percentages of CD4/25/FOXp3 and CD8/25/
FOXp3 in the AD-MSCs group with regard to the control 
group. Studied cytokine levels (IL-4; IL-10, IL-12, IL-21, 
IL-23, and TNF-a) in peripheral blood did not show sig-
nificant variations between groups. Nevertheless, AD-
MSCs group showed lower IL-17 levels (not statistically 
significant) in the post-operative period (placebo group 
IL-17 4.384 ± 3.093; MSC group 2.586 ± 1.436 pg/ml). 
On the other hand, the placebo group presented lower 
post-operative TGFb-1 levels (p<0.05) than the AD-
MSCs group in peripheral blood (placebo group 33.947 
± 14.312 vs. AD-MSCs group 49.504 ± 5.933 pg/ml).
Discussion
In 1993, Thomas Starzl and colleagues discussed 
how many of the enigmas of transplantation 













SBTx + placebo group SBTx + AD-MSCs treatment group 
Figure 3. %CD4/25/FOXp3 variations in peripheral blood, at pre- and 
post-operative period.














Figure 4. %CD8/25/FOXp3 variations in peripheral blood, at pre- and 
post-operative period.Figure 2. Degrees of rejection assessed morphologically. A: mild-
moderate rejection with incipient villous decapitation and predomi-
nantly mucosal lymphoid infiltration. B: intense rejection with high 
 lymphoid infiltrative component in mucosa and intestinal submucosa 
with cryptovillous architectural destructuring. C and D: massive rejec-
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immunology can be explained by chimerism24. In 
2004, Starzl25 related that: “with the discovery in 1992 
of small numbers of donor leukocytes in the tissues 
or blood of long-surviving organ recipients (microchi-
merism), we concluded that organ engraftment was a 
form of leukocyte chimerism-dependent partial toler-
ance. In this initially controversial paradigm, alloen-
graftment after both kinds of transplantation is the 
product of a double immune reaction in which re-
sponses, each to the other, of coexisting donor and 
recipient immune systems results in variable recipro-
cal clonal exhaustion, followed by peripheral clonal 
deletion.” When in 2008, we began to study the action 
of MSCs on SBTx immune response, we considered 
the possibility of achieving a “microchimera” between 
the cells of the donor and the recipient through the 
AD-MSCs immunomodulation potential. 
In 2015, Grant et al.26, on behalf of the Intestinal 
Transplant Association, reported an “intestinal trans-
plant registry report” since 1985, with 2887 transplants 
reported in 2699 patients. This study shows that cur-
rent actuarial patient survival rates are 76%, 56%, and 
43% at 1, 5, and 10 years, respectively, with no improv-
ing in rates of graft loss beyond 1 year. Data suggested 
that grafts including colon segment had better func-
tion, inclusion of a liver component, and maintenance 
therapy with rapamycin were associated with better 
graft survival26. Grant et al.26 referred that results of 
clinical intestinal transplantation had modestly im-
proved over the past decade26. Clinical indications to 
carry out the SBTx are increasing27. In this decade, a 
few clinical studies have been reported using MSCs 
as immunoregulators in SBT; but until now, studies 
have not obtained a conclusive clinical approach28,29. 
Recently, in clinical liver transplantation, immune treat-
ment by means of Th1/Th2 pathway response modifica-
tion with Treg expanded “ex vivo” application has been 
reported and shows a much better future in solid organ 
transplantation to prevent rejection30.
SBTx, in the present study, was orthotopic, similar 
to that performed in human SBTx. AD-MSCs were 
obtained from the fat tissue of the recipient (isogeneic 
rats). AD-MSCs were implanted locally, in anastomo-
ses and intestinal lumen at the moment of surgery. 
Adas et al.31 presented that systemic transplanted 
bone marrow (BM)-MSCs therapy significantly accel-
erated the healing parameters for ischemic colonic 
anastomosis. Although most experimental studies 
employ MSCs obtained from BM (BM-MSCs), we pre-
fer employing MSCs obtained from adipose tissue 
(AD-MSCs) because obtaining them is preferable in 
human clinical practice since they are more easily 
accessed. Plock et al.32 compared immunomodula-
tory efficacy of AD-MSCs and BM-MSCs adminis-
tered intravenously in a hindlimb vascularized 
composite allotransplantation model in rat. They 
found that AD-MSCs and BM-MSCs exhibited strong 
dose-dependent suppressor function “in vitro,” which 
was significantly more pronounced for adipose cells; 
and regulatory T-cell levels were increased with AD-
MSCs and BM-MSCs, but specially in the AD-MSC 
groups, however, AD-MSCs group did not show any 
increase in the survivorship of allograft with respect 
to the BM-MSCs group. In the Plock et al. study,32 all 
animals revealed peripheral multi-lineage chimerism 
at 4 weeks independently of cell type and dosage and 
MSC treatment resulted in long-term (> 120 days) al-
lograft survival in 47% of the animals, which corre-
lated with durable microchimerism in BM and spleen. 
Mattar and Bieback33 carried out a review compiling 
the current literature regarding the similarities and 
differences between three sources for MSCs with a 
special focus on their immunomodulatory effects on 
T-lymphocytes subsets and monocytes, macro-
phages, and dendritic cells, and they found similar 
results to Plock et al.32 and to data obtained from 
review of Gao et al. in 201634.
With respect to the doses of MSCs, there are no-
table differences in the literature, experimental studies 
use between 1 × 106 and 107 cells/animal, we per-
formed some preliminary studies on SBTx rats to fix 
MSC doses and subclinical immunosuppressive treat-
ment doses employing cyclosporine (data unpub-
lished). Finally, we used 4 × 106 MSCs and 0.4 mg/
animal/day.
Our results showed a lower number of ACRs and 
less severity of the rejection in AD-MSCs treated ani-
mals with regard to the control group. Although re-
cently, some authors use BM-MSCs infused through 
the penile vein35,36 with partial success, other authors 
have employed the arterial way without success. We 
think that MSCs have been extensively investigated 
for their potential to regenerate tissue and to modulate 
the immune system. Their characteristic features are 
adherence to tissue and plasticity. Therefore, direct 
application in intestinal lumen and anastomoses in 
SBTx could be a very important factor to prevent re-
jection, but this fact is related to the dose of MSCs.
From the point of view of the immune response, all 
authors agree that MSCs immunomodulate the immune 
response through the Th2 pathway activation. We agree 
with Yang et al.35, whose results in SBTx undergoing 
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BM-MSCs treatment showed an increase of Treg levels 
and upregulation mainly due to increases of TGFb-1. 
Our results showed a significant increase of 
CD4+25+Foxp3+ and CD8+25+Foxp3+ cell percent-
ages in peripheral blood in SBTx rats treated with AD-
MSCs. The increase of CD8+25+Foxp3+ cell percentage 
was greater than the increase of CD4+25+Foxp3+ cell 
percentage. The previous studies37-39 showed that earli-
ness of rejection correlated with the percentage of 
CD8+ cells and the intensity of rejection with numbers 
of CD8+ cells; in addition, we observed a significant 
correlation between apoptosis and rejection, between 
CD8+ and CD54+ with apoptosis and with rejection, 
and between CD8+ and CD54+38. Therefore, CD8+25+ 
cells are essential in rejection. CD54+ is an intercellular 
adhesion molecule-1 that is found on endothelial cells, 
it indicates that the activation of endothelial molecules 
and cells may play an important role in established 
SBTx rejection. Results of the present study highlight 
an increase of CD8+25+Foxp3+ cells in animals under-
going SBTx and AD-MSCs treatment. Until now, this 
fact has not been published. The AD-MSCs group 
showed lower IL-17 levels than the placebo group (not 
statistically significant) in the post-operative period. Be-
sides, the placebo group presented significantly lower 
post-operative TGFb-1 levels than the AD-MSCs group 
in peripheral blood. These variations are in accordance 
with other authors34,36,40.
Conclusions
We think that AD-MSCs induce regulatory immune 
response by increasing Treg percentages and TGFb-1 
levels, thus probably leading to an immune donor-
recipient chimera when AD-MSCs are implanted in 
anastomoses and intestinal lumen in SBTx, leading to 
a lower risk of acute rejection by cell mediation, in the 
first 7 days of the intestinal transplant.
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